Group 1 - The core point of the article is that GlaxoSmithKline has received approval from U.S. health regulators for an additional drug aimed at treating severe asthma, which provides patients with a treatment option that requires less frequent dosing [1][2] Group 2 - The approval of the new drug paves the way for a market entry that offers patients a lower frequency treatment regimen [1][2]